Experienced in Pemphigus Vulgaris

Stephen P. Shumack

St Vincent's Hospital Melbourne
Fitzroy, VIC, AU 
Experienced in Pemphigus Vulgaris
St Vincent's Hospital Melbourne
Fitzroy, VIC, AU 
OverviewLocationsClinical Research

Overview

Stephen Shumack practices in Fitzroy, Australia. Mr. Shumack is rated as an Experienced expert by MediFind in the treatment of Pemphigus Vulgaris. His top areas of expertise are Atopic Dermatitis, Actinic Keratosis, Psoriasis, and Plaque Psoriasis.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Pemphigus Vulgaris.

Gender
Male

Locations

St Vincent's Hospital Melbourne
Fitzroy, VIC, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 06, 2018
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

47 Total Publications

Practice Guidelines for Teledermatology in Australia: 2025 Update.
Practice Guidelines for Teledermatology in Australia: 2025 Update.
Journal: The Australasian journal of dermatology
Published: June 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shumack's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile